ADMA Biologics, Inc. — Quarterly Financial Statements (NASDAQ:ADMA) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Market Capitalization 3.71 B
Employee 685
Founded 2004
CEO N/A
Website www.admabiologics.com
Headquarter Delaware, United States
FIGI BBG002NCK5M5
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

3.71 B Market capitalization

Price to earnings ratio

30.4

Price to sales ratio

—

Dividends per share

—

Dividend yield %

—

News

Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change

ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance

Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues

ADMA Biologics Inc earnings beat by $0.03, revenue fell short of estimates

Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?

Adam Grossman, president of Adma Biologics, sells $337,679 in shares

Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer

NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro

Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know